# C Ray Therapeutics

Source: https://onco.cc/companies/c-ray-therapeutics/  
OnCo record `c-ray-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

C Ray Therapeutics makes radioactive medicines and also manufactures them for other companies. Its own lead treatment, TRC003, carries a radioactive atom to prostate cancer cells and is in an early trial for advanced prostate cancer that no longer responds to hormone treatment.

## Summary

C Ray Therapeutics (Chengdu) Co., Ltd., at 198 Haida Road, Wenjiang District, Chengdu, China, describes itself as a radiopharmaceutical contract research, development and manufacturing organisation offering process development, preclinical evaluation, IND enabling work, clinical supply and commercial cGMP production, and says it has supported 23 actinium-225 labelled projects. It also develops its own products: TRC003 injection, which the company describes as a therapeutic radiopharmaceutical labelled with actinium-225, is in a phase 1/2 trial in adults with PSMA-positive metastatic castration-resistant prostate cancer (NCT07567521, posted May 2026), and TRDC002 is in a phase 1 diagnostic PET/CT study in PSMA-positive prostate cancer (NCT07236112). Its first registered cancer trial, NCT07236112, was posted on ClinicalTrials.gov in November 2025. The company states that by 2024 it had raised more than USD 187 million in total, and that it formed a Radiopharmaceutical Innovation Alliance with United Imaging, Perceptive, Quarkmed, GoBroad Healthcare and Grand Pharmaceutical Group.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: C-Ray; C Ray Therapeutics (Chengdu) Co., Ltd.
- HQ: Chengdu
- Type: radiopharma
- Website: https://www.c-raytherapeutics.com/

## Notes

- Founding year not stated on the company website; a third-party directory gives 2021, which was not confirmed.
- The description of TRC003 as actinium-225 labelled comes from the company's expanded access policy, read as reproduced on the Reagan-Udall Foundation Expanded Access Navigator; the company page itself renders only with JavaScript.
- The isotope used in the TRDC002 diagnostic agent is not stated in the registry title read, so no PET isotope is recorded.
- No individual financing round was confirmed; only the company's stated cumulative total is given.
- Company website read on 29 October 2026.

## Sources

- Official website: https://www.c-raytherapeutics.com/
- Expanded access policy for TRC003 (Reagan-Udall Foundation navigator): https://navigator.reaganudall.org/c-ray-therapeutics-chengdu-co-ltd
- ClinicalTrials.gov: phase 1/2 trial of TRC003 in PSMA-positive mCRPC (NCT07567521): https://clinicaltrials.gov/study/NCT07567521
- ClinicalTrials.gov: phase 1 study of TRDC002 PET imaging in PSMA-positive prostate cancer (NCT07236112): https://clinicaltrials.gov/study/NCT07236112

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Imaging](https://onco.cc/fronts/imaging/), [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- technologies: [PSMA PET](https://onco.cc/technologies/psma-pet/), [Radiopharmaceutical GMP and releasing a drug that decays](https://onco.cc/technologies/radiopharmaceutical-gmp-release/), [Targeted alpha therapy](https://onco.cc/technologies/targeted-alpha-therapy/)
- targets: [PSMA](https://onco.cc/targets/psma/)
- trials: [A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC](https://onco.cc/trials/nct07567521/)

---
JSON: https://onco.cc/api/v1/entities/c-ray-therapeutics.json